Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Today was the first high volume day,so?
Hope to see some new people here soon...After today
The most positive came back,lol
15'S ARE UP AND GETTING SLAPPED
Load the 10's before you left behind!!
Time for the last 14's!
Why to invest in SCIE --->SpectraScience Inc.
Do your own DD on the stock.
-The Company’s lead platform—the WavSTAT® Optical Biopsy System—is in the final stages of a multicenter, 1,200-patient European study and is poised to commence sales in Europe and potentially Saudi Arabia in 2016 and new markets in China and India during 2017.The Wavstat4 is currently already used in some hospitals in Germany,Spain and other European Union countries. The current WavSTAT4 product is initially targeted to the colorectal cancer screening market where recent colonoscopy guidelines have created opportunities for new, improved diagnostic technologies.
-Up to 80% of colorectal biopsies performed are estimated to be identified as normal, non-cancerous tissue. Replacing these invasive physical biopsies with an optical biopsy, as SpectraScience's WavSTAT4 does, reduces risks to patients and may lead to a healthcare cost savings of over $1 billion in the U.S. alone.Currently waiting FDA approval for the USA.
-WavSTAT4 has been designed for ease of integration into the current standard of care. It entails essentially the same process as how physicians screen for cancer today, and is compatible with existing endoscopes. SpectraScience merely adds a layer of diagnostic interpretation and confidence by notifying physicians that, at a particular tissue location, they do not need to take a physical biopsy that they otherwise might have performed.
-Tissue that WavSTAT4 finds to be precancerous or cancerous returns a red “suspect” icon. Unlike the traditional method of visual inspection, there is no ambiguity to the result and no need for physician interpretation.
SpectraScience is further evaluating the potential of its technology in an array of additional indications and using a combination of next-generation, light-based technologies. Clinical results have suggested potential for WavSTAT4 in bladder cancer as well as in other oncology areas. SpectraScience in particular views the esophageal screening market as an opportunity, as endoscopes are the typical diagnostic tool of choice for both colorectal and esophageal screening.
-SpectraScience’s patent portfolio in the field of optical methods to detect cancer, cancer precursors, and tissue abnormalities includes 34 U.S. utility patents, seven U.S. design patents, 25 foreign counterpart patents, and an exclusive license to the Massachusetts General Hospital’s optical forceps patent.
-SpectraScience Inc has signed a distribution agreement with Advanced Medical German Co. (AMG) in Kuwait to be its exclusive distributor in the Middle East in july 2016
Updates on the Wavstat4 or news can hit the newswire any moment!!
Load the 10'S before the news hits!
looking nice here!!Lets see what we can make in POWERHOUR!
SCIELooking ready for a the Breakout!
SCIE Breakout Alert on huge volume!!
SCIEReady for a Break Out!!
Huge volume coming in and big buyers,nobody aint buying 6 million shares if he/she don't believe in the stock
Just a matter of time till this one will explode!!
You saw it totally correct,the believers or coming in!!
Huge buys coming in!!Lets rock
VNDM moved up!!Looks like ready to go!!
Good moment to step in,load cheapies!
Just a matter of time till this one explodes!!!With huge volume
The believers stepped in,you aint investing 6 million shares if you don't believe in a stock
Wavstat4 updates and news expected here!!
Load the cheapies before the news!
Seems like the stock believers are stepping in!
Go SCIE$$
BUYOUT COMING
Nice to see you here,buddy
I agree....
I think its easter...
Just a matter of time ...
Bidsitters at 2's got scared,LOL Bid at 3's almost 30 million
4's printed!
way higher!
After 4 months still no 3's here...LOL
Instead from .0005 to .0024
LOL,yes no 3's
People prefer Scams and MJNA BS with a pump/dump
Waiting for news...or whales I think its cheap enough here!!
Wow another 1 million cheapies,lol
Already made huge money here,dude?LOL
Yes not for flippers,lol
Stock info for new investors --->UNDERVALUED SpectraScience Inc.
-The Company’s lead platform—the WavSTAT® Optical Biopsy System—is in the final stages of a multicenter, 1,200-patient European study and is poised to commence sales in Europe and potentially Saudi Arabia in 2016 and new markets in China and India during 2017.The Wavstat4 is currently already used in some hospitals in Germany,Spain and other European Union countries. The current WavSTAT4 product is initially targeted to the colorectal cancer screening market where recent colonoscopy guidelines have created opportunities for new, improved diagnostic technologies.
-Up to 80% of colorectal biopsies performed are estimated to be identified as normal, non-cancerous tissue. Replacing these invasive physical biopsies with an optical biopsy, as SpectraScience's WavSTAT4 does, reduces risks to patients and may lead to a healthcare cost savings of over $1 billion in the U.S. alone.Currently waiting FDA approval for the USA.
-WavSTAT4 has been designed for ease of integration into the current standard of care. It entails essentially the same process as how physicians screen for cancer today, and is compatible with existing endoscopes. SpectraScience merely adds a layer of diagnostic interpretation and confidence by notifying physicians that, at a particular tissue location, they do not need to take a physical biopsy that they otherwise might have performed.
-Tissue that WavSTAT4 finds to be precancerous or cancerous returns a red “suspect” icon. Unlike the traditional method of visual inspection, there is no ambiguity to the result and no need for physician interpretation.
SpectraScience is further evaluating the potential of its technology in an array of additional indications and using a combination of next-generation, light-based technologies. Clinical results have suggested potential for WavSTAT4 in bladder cancer as well as in other oncology areas. SpectraScience in particular views the esophageal screening market as an opportunity, as endoscopes are the typical diagnostic tool of choice for both colorectal and esophageal screening.
-SpectraScience’s patent portfolio in the field of optical methods to detect cancer, cancer precursors, and tissue abnormalities includes 34 U.S. utility patents, seven U.S. design patents, 25 foreign counterpart patents, and an exclusive license to the Massachusetts General Hospital’s optical forceps patent.
-SpectraScience Inc has signed a distribution agreement with Advanced Medical German Co. (AMG) in Kuwait to be its exclusive distributor in the Middle East in july 2016
NO pump/dump here!